A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer

Mohamad Moussa,Athanasios Papatsoris,Despoina Sryropoulou,Mohamed Abou Chakra,Athanasios Dellis,Lazaros Tzelves

DOI: https://doi.org/10.1080/14656566.2021.1925647

2021-06-02

Expert Opinion on Pharmacotherapy

Abstract:Prostate cancer is one of the most common neoplasms in men. For many years the mainstay of treatment was androgen deprivation therapy, but during last decade many novel agents have emerged, accompanied by increased costs for healthcare systems.In this literature review, the authors provide a pharmacoeconomic review of several pharmaceutical agents used in several disease stages, by summarizing evidence from cost-analysis, cost-effectiveness, cost-utility, cost-saving, cost-benefit and budgetary impact analysis studies.The rapid development of therapeutic agents for prostate cancer has put a great budgetary burden on healthcare systems, since these drugs are prolonging survival and improving quality of life . Since existing data are now mature enough from a number of clinical trials with long-term follow-up, policy makers should propose not only the most clinically effective but also the most cost-effective agents, in order for every patient to gain access at least to some of these therapies. Docetaxel addition seems to be a cost-effective option, when compared to both abiraterone and enzalutamide (due to costs related to acquisition and side effects). Cabazitaxel is a strong candidate after docetaxel failure, while both denosumab and bisphosphonates are cost-effective for reducing skeletal-related events in metastatic disease.

pharmacology & pharmacy

What problem does this paper attempt to address?

This paper aims to solve the problem of pharmacoeconomic evaluation in the treatment of prostate cancer. Specifically, the paper focuses on the cost - effectiveness analysis of multiple drug treatment regimens in different stages of prostate cancer (such as hormone - sensitive stage, castration - resistant stage, etc.). With the rapid development of new treatment drugs in recent years, although these drugs have prolonged the survival time of patients and improved their quality of life, they have also brought a huge economic burden to the medical system. Therefore, policy - makers need to find a balance between clinical effectiveness and cost - effectiveness to ensure that every patient can obtain treatment opportunities for at least some of these therapies.

By reviewing the literature, the paper summarizes the evidence obtained from cost analysis, cost - effectiveness, cost - utility, cost - saving and budget - impact analysis studies, covering multiple drug treatment regimens, such as Docetaxel, Cabazitaxel, Enzalutamide, Abiraterone, etc. Through a comprehensive evaluation of the cost - effectiveness of these drugs, the paper provides a basis for decision - makers to select the most cost - effective treatment regimens, especially in different stages of prostate cancer.

For example, the paper points out that when compared with Abiraterone and Enzalutamide, the addition of Docetaxel seems to be a cost - effective choice, mainly because of the lower costs associated with acquisition costs and side effects. In addition, Cabazitaxel is a strong candidate drug after the failure of Docetaxel, and Denosumab and Bisphosphonates are also cost - effective choices in reducing bone - related events in metastatic diseases.

In conclusion, through detailed pharmacoeconomic analysis, this paper provides an important reference for the selection of prostate cancer treatment regimens, which helps to optimize the allocation of medical resources and ensure that patients can receive effective treatment.